This review addresses two questions. First, why does clozapine apparently occupy low levels of dopamine D2 receptors in patients, in contrast to all other antipsychotic drugs which occupy 70-80% of brain dopamine D2 receptors? Second, what is the receptor basis of action of antipsychotic drugs which elicit low levels of Parkinsonism?
Apparent low occupancy of dopamine D2 receptors by clozapine
Antipsychotic drugs, when given at clinically effective doses, generally occupy between 70% and 80% of brain dopamine D2 receptors in patients, [1] [2] [3] [4] [5] [6] [7] as measured in the human striatum (ie the caudate nucleus and/or the putamen). Clozapine, however, has consistently been an apparent exception. For example, in patients taking therapeutically effective antipsychotic doses of clozapine, this drug only occupies between 0% and 50% of brain dopamine D2 receptors, as measured by a variety of radioligands using either positron tomography 1, 2, [8] [9] [10] [11] [12] [13] or single photon tomography. [14] [15] [16] [17] [18] [19] Although the apparently low occupancy of D2 by clozapine might suggest that D2 may not be the major antipsychotic target for clozapine (because clozapine binds to many other neurotransmitter receptors) 20 it is necessary to analyse these low occupancy data in the light of recent evidence showing that the occupancy of a receptor by a drug depends on the radioligand used to measure that receptor. [21] [22] [23] [24] [25] [26] This latter finding shows that the occupancy is higher when radioligands with higher dissociation constants are used.
Using this latter finding, therefore, one objective in this mini-review was to determine indirectly the occupancy by clozapine of brain dopamine D2 receptors that must in fact be taking place in vivo in patients being treated with clozapine in the absence of any radioligand. This analysis indicates that clozapine, at therapeutic doses, occupies high levels (of the order of 70-80%) of dopamine D2 receptors in the striatum, similar to the occupancies found with therapeutic doses of other antipsychotic drugs, and that clozapine may possibly occupy even higher levels in the limbic regions where the endogenous synaptic dopamine is lower than that in the striatum.
Potencies of antipsychotic drugs at dopamine D2 receptors
The occupancy of receptors can be determined directly by radioligand tomography or indirectly by measuring the concentration, C, of the antipsychotic drug in the spinal fluid. Using the latter method, the percent of receptors occupied, f, is equal to C/(C + K), where K is the dissociation constant (or inhibition constant) of the antipsychotic drug at the D2 receptor.
The concentration method, therefore, provides an independent estimate of receptor occupancy by antipsychotic drugs. The free concentrations of antipsychotics in the cerebrospinal fluid and in the plasma water (ie, not bound to plasma proteins) have previously been reviewed, 27 although an important revision to the data for clozapine is added below.
In order to derive the clinical receptor occupancies from the antipsychotic concentrations, it is necessary to have accurate K values, as indicated in the above equation for the occupancy, f. These K values, however, differ considerably between laboratories for a variety of technical reasons. 27, 28 Hence, it is essential to have K values for all antipsychotic drugs from a single laboratory using standard conditions.
As noted above, recent evidence shows that the antipsychotic occupancy or the antipsychotic K (which is the concentration for 50% occupancy of a receptor) depends on the radioligand used to measure that receptor. [21] [22] [23] [24] [25] [26] For example, antipsychotic drugs which bind loosely (ie, with high K) to the receptor are less able to compete against tightly bound radioligands (ie, with low K).
Hence, it has been necessary to obtain true dissociation constants which are independent of the radioligand used. This has now been done for many antipsychotic drugs at human cloned dopamine D2, D3, D4 and serotonin 2A receptors, and a list of these values is given in Table 1 (summarized from Refs 21-26) . Although the technical explanation for the apparent dependence of the antipsychotic dissociation constant on the radioligand is not known, detailed experiments have shown that it is not a result of radioligand depletion. 21 Although most laboratories use final incubation volumes of between 1 and 2 ml, larger volumes reduce this apparent dependence of the antipsychotic dissociation constant on the radioligand. 21 In fact, using very large volumes of 10 ml leads to experimental dissociation constants for the antipsychotic drugs 22 which are almost identical to the radioligandindependent dissociation constants in Table 1 . Clozapine, for example, has a K of 35-59 nM for D2 using [ 3 H]raclopride, 22 compared to a value of 44 nM for the radioligand-independent dissociation constant (Table  1) . Similarly, haloperidol has a K of 0.5-0.6 nM, using the very large volumes, 22 compared to the radioligandindependent dissociation constant of 0.4 nM in Table 1 . Hence, the large-volume method and the radioligand-independent method provide data which confirm one another.
Clinical antipsychotic potencies correlate with true dissociation constants at D2
These antipsychotic drug dissociation constants, which are independent of the radioligand used (Table 1) , correlate with the antipsychotic doses used clinically ( Figure 1 ). This correlation agrees with previous work. [29] [30] [31] [32] Of the many antipsychotic drugs shown in Figure 1 , only chlorpromazine and thioridazine deviate significantly from the overall correlation. The deviations for these two drugs, however, disappear when the spinal fluid concentrations of the various antipsychotic drugs are considered (next section).
Therapeutic levels of antipsychotic drugs occupy high levels of brain dopamine D2 receptors
The occupancy of brain dopamine D2 receptors, under clinically therapeutic conditions, can now be indirectly determined from the antipsychotic drug average concentrations in the spinal fluid and using the radioligand-independent dissociation constants in Table 1 .
The dissociation constant, K, in Table 1 is defined as the antipsychotic concentration required for 50% occupation of the receptor in the absence of dopamine or any other ligand. In reality, however, because the antipsychotic drug must compete with dopamine within the synaptic space, the antipsychotic concentration to block 50% of the receptors in the presence of dopamine (C 50% ) will be higher than that in the absence of dopamine, in accordance with the equation
, where D is the effective dopamine concentration in the synapse and where D2 High is the dissociation constant of dopamine at the highaffinity state of the dopamine D2 receptor.
Although the effective concentration of dopamine in the synapse is not known, it is considered to be anywhere between 1 nM and 45 nM. The basal level of synaptic dopamine in the rat nucleus accumbens has been estimated to be 4 nM. 35 At a firing frequency of five impulses per second, the synaptic dopamine in rat striatum has been estimated to be about 200 nM in the first few millisec and then to rapidly fall to 1-2 nM within 200 millisec. 36 The resting synaptic dopamine concentration in the human striatum has been indirectly estimated to be about 45 nM. 37 The dopamine D2 receptor can exist in either a highor a low-affinity state for dopamine, wherein the high- Table 1 Dissociation constants for antipsychotic drugs at the human cloned dopamine D2, D3, D4 and serotonin-2A receptors. The binding of three different radioligands was inhibited by each antipsychotic drug. These three inhibition constants were then related to the membrane/buffer partition coefficients of the radioligands. By extrapolating to 'zero' partition coefficient, one obtained the true dissociation constant which was independent of the radioligands. [21] [22] [23] [24] [25] [26] This dissociation constant agreed with that determined directly using the radioactive form of the same antipsychotic drug. Abbreviations: Ȱ YM-09151-2; ՚ SM 9018; * rat cortex tissue 38 The dissociation constant of dopamine at D2 High is between 2 and 10 nM [38] [39] [40] [41] [42] [43] [44] [45] with an average of 7-7.5 nM, when using [ 3 H]spiperone. [38] [39] [40] [41] [42] [43] [44] [45] However, in the same way as the dissociation constant of an antipsychotic drug depends on the radioligand used (see above), [21] [22] [23] [24] [25] [26] the dissociation constant of dopamine at the D2 receptor also depends on the radioligand used. For example, the dissociation constants of antipsychotic drugs, as well as dopamine agonists, are consistently lower by a factor of 3 when using [
3 H]raclopride, compared to the values obtained when using [ 3 H]spiperone. [21] [22] [23] [24] [25] [26] Thus, the radioligand-independent values are even lower, by a factor of 5, than the dissociation constants obtained using [ 3 H]spiperone. [21] [22] [23] [24] [25] [26] In fact, the radioligand-independent dissociation constant of dopamine at the high-affinity state of the D2 receptor is indeed one-fifth that of 7.5 nM or 1.5 nM (data not shown).
Although the synaptic average concentration of dopamine, D, is not known, it appears that D is of the same order of magnitude as the dopamine K for D2 High . Hence, with this single assumption that D D2 High , the
In addition, the fraction, f, of D2 receptors occupied by an antipsychotic at a concentration C is C/(C + K). Using this formula, it may be shown that the concentration of antipsychotic drug needed to occupy 75% of the D2 receptors (ie C 75% ) is about three times higher than that required to occupy 50% of the receptors, C 50% . In other words, C 75% = 3 × C 50% , or C 75% = 6 × K.
Hence, using the K values in Table 1 , the antipsychotic C 75% concentrations were calculated according to the latter equation and graphed in Figure 2 . These values were graphed vs the therapeutic concentrations of the antipsychotic drugs in the cerebrospinal fluid or in the plasma water (ie, corrected for drug binding to the plasma proteins).
The therapeutic concentrations used in Figure 2 have previously been summarized, 27 with the exception of clozapine for which new data have appeared. 46 The average concentration of clozapine in plasma found in patients taking clinically effective doses of clozapine is 292 ng ml −1 or 894 nM. The concentration of clozapine in the spinal fluid is 20% of that in the plasma [46] [47] [48] 
Figure 1
The clinical antipsychotic doses 27, 33, 34 correlate with the antipsychotic dissociation constants in Table 1 . The deviations for chlorpromazine and thioridazine disappear when the spinal fluid concentrations of the antipsychotic drugs are considered (Figure 2 ). The clinical dose for cis-flupentixol was taken as half the standard dose used clinically (which is the racemate).
or 179 nM. In addition, the average ratio between norclozapine and clozapine is 0.59, [49] [50] [51] [52] [53] [54] [55] resulting in a norclozapine concentration of 106 nM in the spinal fluid. However, because norclozapine has a dissociation constant of 100 nM at D2, compared to a value of 44 nM for clozapine (Table 1) , the spinal fluid concentration of 106 nM norclozapine is equivalent to a 'clozapine-like D2-blocking concentration' of 106 nM × 44 nM/100 nM or 47 nM. Hence, the average D2-blocking concentration of clozapine (including norclozapine in clozapine equivalents) in the spinal fluid is 179 nM + 47 nM or 226 nM.
The line in Figure 2 is the line for identical values between the C 75% and the therapeutic free concentration of antipsychotic drug in the spinal fluid or plasma water. It may be seen that the C 75% values for all the antipsychotic drugs (for which data are available) fall on this line of identity. In other words, based on the single assumption that the effective synaptic dopamine is similar to the K value of dopamine for the high-affinity state of D2, one may conclude that approximately 70-80% of dopamine D2 receptors are occupied in the human striatum by antipsychotic drugs under therapeutic conditions.
The results in Figure 2 are not a coincidence, because similar calculations for the dopamine D3 and dopamine D4 receptors did not reveal any constant percent occupancy for all the antipsychotic drugs ( Figure 3 ). The D2-blocking action of antipsychotic drugs, depending on the type and dose of drug used, commonly elicits Parkinsonism and other extrapyramidal clinical signs in patients.
What is
It has often been suggested that the blockade of serotonin-2A receptors may alleviate the Parkinsonism caused by D2 blockade. It has been difficult, however, to obtain clear behavioural data supporting this important principle. For example, neuroleptics which block both D2 and serotonin-2A receptors also elicit Parkinsonism or catalepsy. 56 Second, a high degree of serotonin-2A receptor occupancy (95%) by risperidone (6 mg day
) did not prevent extrapyramidal signs in 6 out of 7 patients. 57 Third, there is no significant correlation between the cataleptic doses of neuroleptics and the ratio of the antipsychotic dissociation constants at D2 and at serotonin-2A receptors, as shown in Figure 4 , using the values in Table 1 . 24, 25 Fourth, ritanserin (2 mg kg −1 s.c.) had no effect on raclopride-induced catalepsy, using either maximal (4 mg kg −1 s.c.) or sub-maximal (0.2 mg kg −1 s.c.) doses of raclopride. 58 However, in apparent conflict with this latter negative result, Lucas et al It is also uncertain whether serotonin-2A receptors have any role in the antipsychotic process, because the blockade of serotonin-2A receptors 'is not a prerequisite for the antipsychotic effect'. 60, 61 Although MDL 100 907 selectively blocks serotonin-2A receptors, 62 ritanserin blocks both serotonin-2A and -2C receptors. 63, 64 Although clozapine blocks serotonin-2C receptors at concentrations of the order of 100 nM, 64, 65 no clear relation was found between the Parkinson-avoiding potencies of antipsychotics and their potencies at the serotonin-2C receptor 64 (note, although Refs 64 and 65 refer to serotonin-1C, this receptor was renamed serotonin-2C in keeping with its serotonin-2-like amino acid sequence). 66 It should also be mentioned here that clozapine is of the order of 20-to 50-fold more potent in blocking muscarinic acetylcholine receptors than blocking dopamine D2 receptors, making clozapine an extremely potent anticholinergic drug. Clozapine blocks muscarinic receptors between 1.5 nM and Figure 2 The concentrations of various neuroleptics needed to occupy 75% of the D2 receptors, C 75% , are essentially identical to the therapeutic concentrations of neuroleptics found in the spinal fluid or in the plasma water in patients. Because endogenous synaptic dopamine competes with the neuroleptic, the C 75% values were six times higher than the neuroleptic dissociation constants at the D2 receptor (Table 1) 
Antipsychotic drugs which bind more loosely than dopamine to dopamine D2 receptors elicit little or no Parkinsonism
A dominant factor in determining whether a particular antipsychotic drug elicits Parkinsonism is whether it binds more tightly or more loosely than dopamine at the dopamine D2 receptor. This is illustrated in Figure 6 .
Thus, for those antipsychotic drugs which elicit little or no Parkinsonism, it appears that the high endogenous dopamine in the human striatum must outcompete the more loosely bound antipsychotic at the D2 receptor. The endogenous dopamine in the limbic brain regions (eg, frontal cortex, cingulate gyrus, etc) is of the order of one-tenth that in the striatum, and so the lower synaptic endogenous dopamine in the limbic regions would not be as effective in out-competing the administered antipsychotic drug. Thus, the D2 occupancy in the human limbic regions would be expected to be somewhat higher than that in the human striatum. Such data are not yet available.
The case of raclopride is interesting because many studies [67] [68] [69] have shown that radioraclopride can be displaced by 10-30% by endogenous dopamine. [67] [68] [69] [70] The data in Table 1 indicate that the dissociation constant for raclopride is approximately 1 nM (between 0.64 and 1.6 nM), very close to the value of 1.5 nM for dopamine at the high-affinity state of the D2 receptor ( Figure 6 ). Thus, while some raclopride is actually displaced by endogenous dopamine, raclopride is known to cause extrapyramidal side-effects. It is possible, therefore, that the magnitude of displacement by dopamine is important clinically in order to avoid Parkinsonism. Previous work 68 has shown that dopamine less readily displaces the more hydrophobic radioligands of the haloperidol-type. Thus, there appears to be a crude correlate between the magnitude of displaceability and Parkinsonism.
This separation of antipsychotic drugs into 'loose' and 'tight' binding to D2, relative to that for dopamine, is consistent with the findings by Kalkman et al. 71 These authors were able to reverse catalepsy induced by olanzapine and loxapine (both more loosely bound than dopamine), but were not able to reverse that by Figure 3 The therapeutic concentrations of various antipsychotic drugs consistently occupy 75-76% of dopamine D2 receptors (data from Figure 2 ), but similar calculations for the dopamine D3 and dopamine D4 receptors did not reveal any constant percent occupancy for all the antipsychotic drugs. CPZ, chlorpromazine; Cloz., clozapine; Halo., haloperidol; Molin., molindone; Olan., olanzapine; Raclo., raclopride; Remox., remoxipride; Sulp., S-Sulpiride; Thior., thioridazine; Flupen., cis-flupentixol; per., perphenazine. 
Figure 6
Antipsychotic drugs which bind more tightly than dopamine at the dopamine D2 receptor elicit Parkinsonism, while those which bind more loosely than dopamine elicit little or no Parkinsonism or other extrapyramidal clinical signs in patients. The radioligand-independent value for the dissociation constant of dopamine at the high-affinity state of the dopamine D2 receptor is 1.5 nM (see text). Data from Table 1. haloperidol (Kalkman HO, Tricklebank MD, 1997, personal communication).
Therapeutic levels of clozapine occupy high levels of D2 receptors, using brain imaging
The finding of high occupancy of D2 receptors by maintenance doses of clozapine, shown in Figure 2 , can be confirmed independently from published data using PET (positron emission tomography) or SPET (single photon emission tomography).
It has been consistently claimed that clozapine only occupies between 0% and 50% of brain dopamine D2 receptors, as measured by a variety of radioligands using either positron tomography 1, 2, [8] [9] [10] [11] [12] [13] or single photon tomography. [14] [15] [16] [17] [18] [19] This is in contrast to the D2 occupancies of 70 -80% for the typical neuroleptics.
As noted above, it is necessary to analyse these low occupancy data in the light of evidence showing that the occupancy of a receptor depends on the radioligand used to measure that receptor. [21] [22] [23] [24] [25] [26] This latter finding shows that the occupancy rises when radioligands with higher dissociation constants are used.
This important principle also holds true for the occupancy of D2 by clozapine when using various radioligands with PET or SPET, as illustrated in Figure 7 . This Figure shows that 72 Clozapine occupied higher levels of D2 receptors, between 30% and 47%, [14] [15] [16] [17] [18] [19] when [ 123 I]iodobenzamide was used with its higher dissociation constant of 0.43-0.49 nM. 73, 74 Finally, the highest level of D2 receptors, 50%, was occupied by clozapine 2 (Kapur S, personal communication, 1996) when [ 11 C]raclopride was used with its dissociation constant of 0.6-1 nM ( Table 1) .
The observation that the D2 occupancy by clozapine depends on the radioligand used ( Figure 7 ) is similar to that found in measuring the occupancy of the dopamine transporter. 75 Cocaine, with its dissociation constant, K d , of 60 nM, 76, 77 does not displace [ Extrapolating the relation shown in Figure 7 to the dissociation constant of 1.5 nM for dopamine (at the high-affinity state of D2) reveals that 75% of D2 receptors must in fact be occupied by clozapine in patients taking maintenance doses of clozapine in the absence of any radioligand.
Clinical implications and conclusions
Clozapine fits the rule of high levels of blockade of dopamine D2 receptors by neuroleptics when patients take effective maintenance doses of antipsychotic medication, a rule worked out by Farde and colleagues. [1] [2] [3] There are a number of clinical implications with respect to the properties of antipsychotic drugs summarized in this review, as follows: Table 1 ). Extrapolating this relation to the dissociation constant of 1.5 nM for dopamine (at the high-affinity state of D2) reveals that 75% of D2 receptors must be occupied by clozapine in patients in the absence of any radioligand.
Is D2 block a necessary minimum for antipsychotic action?
The consistent finding of high occupancy of D2 for all neuroleptics, including clozapine, suggests that the blockade of D2 is an essential minimal requirement for clinical antipsychotic action in those patients who respond to neuroleptics. It is, of course, well known that many schizophrenia patients may not clinically improve despite high occupancy (Ͼ75%) of their D2 receptors. [78] [79] [80] [81] This supports the long-standing assumption that there may be more than one subtype of schizophrenia.
Do therapy-resistant patients respond to clozapine or remoxipride via D2-blockade?
Clozapine is selective for the dopamine D4 receptor with a K value of 1.6 nM, compared to 3.5 nM for the serotonin-2A receptor and 44 nM for the D2 receptor (Table 1) . Despite the selectivity for D4, however, the clinical antipsychotic action of clozapine appears to reside in its D2-blocking ability with its 'loose' blockade of D2 at 44 nM, primarily based on the findings in Figures 2 and 7 that clozapine fits the universal rule of 75% blockade for clinical antipsychotic action.
It has often been stated that D2 blockade is inadequate to explain the clinical antipsychotic action of clozapine because clozapine has a low occupancy of D2, and, second, because clozapine is clinically effective in 30% of patients who are resistant to haloperidol and similar traditional D2-blocking drugs. 82 Such treatment-resistant patients, however, also respond (sometimes dramatically) to remoxipride, [83] [84] [85] which is extremely selective for D2 (Table 1) . In fact, remoxipride clinically improves at least 30% of treatmentresistant schizophrenia patients. 83 This experience with remoxipride indicates that treatment-resistant patients may still improve via D2-blockade when using a low potency drug such as clozapine (K = 44 nM at D2) or remoxipride (K = 30 nM at D2).
Why do many patients suddenly relapse when stopping clozapine?
Patients taking clozapine often relapse within days of stopping clozapine (see Refs in References 86 and 87). Because clozapine is loosely bound to the dopamine D2 receptor (K = 44 nM), clozapine is readily displaced by any sudden pulse of endogenous dopamine arising from emotional or physical activity. In fact, both R Conley 86 and Pickar et al 88 observed that the D2 occupancy by clozapine readily decreased upon clozapine withdrawal, in contrast to the 2 weeks or more of residual occupancy of D2 by traditional neuroleptics. 89 Any sudden surge of impulse-triggered release of endogenous dopamine will quickly displace any residual clozapine and may lead to a sudden clinical relapse. Table 2 summarizes this point that the relatively more rapid offset of drugs such as clozapine could result in a higher risk of earlier relapse when compared to the more traditional haloperidol and chlorpromazine drugs which are more tightly bound to the D2 receptor.
How can neuroleptic-induced Parkinsonism be minimized?
Although it may be trite to repeat the adage that low doses of neuroleptics elicit low levels of extrapyramidal signs, the present analysis emphasizes this principle once again. Hence, although at least 70-75% occupancy is needed for antipsychotic action, D2 occupancy needs to remain below 80% in order to avoid extrapyramidal signs. Clinical dosing schedules, therefore, may be adjusted accordingly by building up the dose to a level where EPS occurs after which the dose may be reduced by half. This maintains the 75% occupancy of D2 and is a classical clinical strategy which has been used since the advent of neuroleptics. 92 Hence, once sufficient data become available using other radioligands, it appears that these neuroleptics (remoxipride, seroquel, sertindole and ziprasidone) would also extrapolate under therapeutic conditions to occupy approximately 75% of D2 receptors under therapeutic conditions.
In treating L-DOPA-induced psychosis, does clozapine or remoxipride also block 75% of D2 receptors?
The psychosis caused by L-DOPA or bromocriptine in Parkinson's Disease can be readily treated by low doses of either clozapine 49, [93] [94] [95] [96] [97] or remoxipride. 98 The average dose for clozapine is 55 mg day −1 (for 51 patients), [93] [94] [95] [96] [97] while that for remoxipride is 150 mg day −1 , 98 much lower than that used in schizophrenia for either drug (Figure 1 ).
These lower doses follow directly from the wellknown fact that 90-99% of the brain dopamine has been depleted in Parkinson's disease. Hence, there is virtually no endogenous dopamine to compete against clozapine or remoxipride. The low dose of clozapine corresponds to a low spinal fluid concentration of clozapine and norclozapine, estimated to be of the order of 60 nM (given that the unbound clozapine is 20% of the total plasma clozapine). 46 Under these conditions, the fraction of D2 receptors occupied would be about 60%
* . This D2 occupancy by clozapine may be even lower, possibly 20%, if the estimated concentration of 10 nM (unbound) is used from four Parkinson patients who developed psychosis, 49 and using 20% as the fraction of unbound clozapine. Because the D2 occupancy by clozapine in Parkinson patients has not been directly examined, however, the D2 occupancy by clozapine in such patients remains uncertain.
Despite this uncertainty about the occupancy of D2 by clozapine in Parkinson patients, the occupancy of the dopamine D4 receptors by clozapine would be at least 75% † , because the K for clozapine at D4 is 1.6 nM ( Table 1) . At the lowest clozapine concentration, the D4 occupancy would still be at least 86% ‡ . However, the possible antipsychotic effect of D4 receptor blockade is still not known.
The treatment of L-DOPA psychosis by 150 mg day
of remoxipride, on the other hand, would be expected to be associated with about 73% § occupancy of dopamine D2 receptors, in accord with the general rule of 75% D2 block for antipsychotic action. Would high doses of clozapine or remoxipride, exceeding 80% D2 occupancy, cause Parkinsonism?
Although clozapine occupies 75% of D2 receptors when used at 300-400 mg day −1 , higher doses may 19 and may not 2 result in higher D2 occupancy, but do not result in Parkinsonism. The situation for remoxipride may be identical, although insufficient data exist. 1 As discussed above, it appears that clozapine and remoxipride, weakly bound to D2 (see Table 1 ), are readily displaced by synaptic dopamine, which may be transiently very high during brief bursts of nerve impulses known to occur in the motor pathway, 99 thus obviating Parkinsonism.
Will the new antipsychotic drugs with low affinity for D2 and with low risk for Parkinsonism also cause less tardive dyskinesia?
It is likely that those antipsychotic drugs which elicit less Parkinsonism by virtue of their low affinity for D2 (in comparison to dopamine) may result in less tardive dyskinesia. This is discussed by Casey. 100 Essentially, by its high affinity for the D2 receptor, the endogenous dopamine effectively removes the D2-blocking action in the putamen and the caudate nucleus of more loosely associated antipsychotic drugs, thus sparing the lingering and injurious action which antipsychotic drugs have on cell membranes. 101 
